Currently, there are no widely available diagnostic tools specifically for detecting colibactin-producing E. coli in clinical settings. However, advancements in genomic sequencing and metagenomics are paving the way for the development of such tools. These technologies could potentially identify individuals at higher risk for colibactin-related cancers by analyzing their gut microbiome composition.
